Published in Int J Parasitol Drugs Drug Resist on September 25, 2015
An In Vitro/In Vivo Model to Analyze the Effects of Flubendazole Exposure on Adult Female Brugia malayi. PLoS Negl Trop Dis (2016) 0.76
Cyclodextrins and their pharmaceutical applications. Int J Pharm (2006) 2.89
Lymphatic filariasis and onchocerciasis. Lancet (2010) 2.75
Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol (2009) 1.96
Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis (2008) 1.88
Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther (2011) 1.05
Bioavailability and its assessment. J Vet Pharmacol Ther (2004) 1.02
Comparative assessment of albendazole and triclabendazole ovicidal activity on Fasciola hepatica eggs. Vet Parasitol (2009) 0.98
Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis. Filaria J (2003) 0.97
Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. Parasitol Int (2009) 0.95
Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin. J Control Release (2002) 0.95
SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm (2004) 0.93
Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int J Pharm (2003) 0.92
Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. Antimicrob Agents Chemother (2011) 0.91
Comparative plasma disposition kinetics of albendazole, fenbendazole, oxfendazole and their metabolites in adult sheep. J Vet Pharmacol Ther (1995) 0.91
Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers. Antimicrob Agents Chemother (2004) 0.89
Measurement of ivermectin concentrations in target worms and host gastrointestinal tissues: influence of the route of administration on the activity against resistant Haemonchus contortus in lambs. Exp Parasitol (2012) 0.88
Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability. J Vet Pharmacol Ther (2004) 0.85
Hepatic and extra-hepatic metabolic pathways involved in flubendazole biotransformation in sheep. Biochem Pharmacol (2008) 0.84
Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations. PLoS Negl Trop Dis (2014) 0.83
Comparison of minipig, dog, monkey and human drug metabolism and disposition. J Pharmacol Toxicol Methods (2014) 0.82
Visual loss during oral diethylcarbamazine treatment for onchocerciasis. Lancet (1979) 0.82
Nematodicidal activity of flubendazole and its reduced metabolite on a murine model of Trichinella spiralis infection. Chemotherapy (2012) 0.82
Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution. BMC Vet Res (2012) 0.81
Uptake of albendazole and albendazole sulphoxide by Haemonchus contortus and Fasciola hepatica in sheep. Vet Parasitol (2000) 0.81
Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-beta-cyclodextrin following subcutaneous injection in sheep. Int J Pharm (2010) 0.80
Comparative drug systemic exposure and clinical efficacy against resistant nematodes in lambs treated with different albendazole formulations. J Vet Pharmacol Ther (2011) 0.80
The effect of a short-term reduction in feed on the pharmacokinetics and efficacy of albendazole in sheep. Aust Vet J (1995) 0.78